Compare Bit Digital Inc (BTBT) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

BTBT trades at $1.44, up 10.77% over 24 hours, but faces a bearish technical outlook with 14 sell signals against 2 buy signals. The company reported a net loss of $80.32 million in 2025, with a negative net income margin of -145.45%, though it maintains a gross profit margin of 55.57%. Recent earnings have been mixed, with a beat in Q3 2025 but misses in subsequent quarters. The stock is closely watched by investors ahead of its Q2 2026 earnings release on August 13, 2026.

The outlook is challenged by persistent losses and negative cash flow from operations, offset by strong financing inflows. Analyst consensus is bullish with a 100% buy rating from two firms and a $5.12 average price target, suggesting significant upside potential if the company can improve profitability. Key risks include execution challenges, competitive pressures, and reliance on external financing to sustain operations.

Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.

The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.